Trulicity® Lawsuit

Trulicity®, a weekly injectable medication made by Eli Lilly to treat type 2 diabetes, may cause a sudden, irreversible eye condition known as NAION. If you took Trulicity and experienced unexpected vision loss, a Trulicity lawsuit may allow you to pursue compensation.

Sokolove Law has spent more than 45 years fighting on behalf of injured patients, recovering over $1.6 Billion for those harmed by dangerous drugs or medical devices. Call (800) 995-1212 to see if you may have a case.

Get a Free Trulicity Case Review

Is There a Lawsuit Against Trulicity?

Trulicity belongs to a class of medications called GLP-1s, which have been linked to a type of vision loss known as non-arteritic anterior ischemic optic neuropathy (NAION). Trulicity users have submitted over 1,300 reports of visual impairment to the U.S. Food & Drug Administration (FDA).

Currently, at least 200 lawsuits are pending against companies that make GLP-1 medications over the connection to NAION.

Lawsuits against Trulicity maker Eli Lilly claim that the company:

  • Was aware, or should have been aware, of mounting evidence linking GLP-1s to NAION
  • Failed to update Trulicity's warning label to reflect this risk
  • Continued promoting the drug to millions of patients without disclosing what the data was showing
  • Chose profit over transparency, leaving patients to discover the risk only after they were harmed

The effects of NAION can be life-altering. Victims may be able to pursue compensation for their medical bills, pain and suffering, and more. Every state has a statute of limitations for product liability cases, so you may have as little as 1 year to file your legal claim.

If your vision changed suddenly after starting a GLP-1, Trulicity lawyers at Sokolove Law may be able to fight for compensation on your behalf.

Get the Help You Deserve

If you developed NAION after using Trulicity, we may be able to help you file a lawsuit and pursue compensation for your injuries.

Contact Us Now

Can Trulicity Affect Your Eyes?

There may be a 76% higher risk of developing NAION for diabetes patients who take GLP-1s, according to JAMA Network Open. In NAION, blood flow to the optic nerve is cut off, resulting in tissue damage within a matter of hours.

Patients diagnosed with NAION commonly report:

  • Waking up with vision already altered, with no warning signs the night before
  • A blind spot or shadowed area covering part of what they see out of one eye
  • Vision that doesn't return to normal in the days or weeks that follow
  • No pain accompanying the vision change, which can make it easy to dismiss at first

“Consumers deserve to know about all of the potential side effects linked to their medications. Without that information, they can't make a truly informed decision about their own health."
Kristina Berkover, Sokolove Law Attorney

As swelling of the optic nerve goes down, some patients may regain a small amount of vision over time. For most, however, the loss is permanent and may get worse. Many people are left adjusting to changes in how they see the world — and how they live their lives.

About a third of people with NAION lose even more vision while the eye is still swollen, and 15% develop the condition in the other eye within the next 5 years, according to the North American Neuro-Ophthalmology Society.

If you took Trulicity and experienced vision changes, our team can help you understand your options. Call (800) 995-1212 for a free case review.

Do You Qualify to File a Trulicity Side Effects Lawsuit?

To be eligible to file a lawsuit, your lawyer must gather evidence showing a connection between Trulicity and your vision loss. For those who develop NAION, the consequences can be permanent, and legal action may be possible.

You may have grounds for a Trulicity side effects lawsuit if you:

  • Used a GLP-1 medication like Trulicity, Ozempic®, Wegovy®, Rybelsus®, Zepbound®, Mounjaro®, or Saxenda®
  • Experienced serious health issues like vision loss from NAION in one or both eyes after starting the drug

There's only a limited amount of time to pursue a Trulicity side effects lawsuit due to laws called statutes of limitations. The deadline varies by state but can be as short as 1 year, so it's important to contact an attorney as soon as possible.

How Filing a Lawsuit Against Trulicity Works

Pursuing a claim against a pharmaceutical company can feel like an uphill battle, especially while you're adjusting to permanent vision loss. Sokolove Law is built to carry that weight so you don't have to.

When you work with our team, we can:

  • Determine if you may have a claim during a free legal consultation
  • Gather medical documentation and treatment records that support your claim
  • File your Trulicity lawsuit before your state's statute of limitations runs out
  • Handle settlement negotiations with Eli Lilly and any other parties involved
  • Take your case in front of a judge or jury if a settlement is unable to be reached

“When corporations fail to do the right thing, the legal system gives people the opportunity to seek accountability.”
Drake Claxton, Sokolove Law Attorney

 A leading Trulicity attorney at Sokolove Law can develop your claim against Trulicity so you can focus on your health and your family. Our team works to make the process as simple as possible. 

Call (800) 995-1212 now to see if you may be able to seek compensation from a NAION lawsuit. It costs nothing to speak with us.

Trulicity Lawsuit 2026 Update

The legal landscape around GLP-1 drugs and vision loss has developed quickly, including lawsuits against Trulicity maker Eli Lilly. Patients in NAION cases asked federal courts to consolidate dozens of claims into a multidistrict litigation (MDL).

An MDL is not the same as a Trulicity class action lawsuit. Like a class action, an MDL consolidates many cases so they share pretrial proceedings. However, victims in an MDL still pursue their own claims rather than becoming part of a class that shares one settlement or verdict.

Here's what to know about the Trulicity lawsuit in 2026:

  • MDL name: In re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation (MDL No. 3163)
  • Court: U.S. District Court for the Eastern District of Pennsylvania
  • Judge: The Honorable Karen S. Marston
  • Defendants: Eli Lilly and Company and Novo Nordisk
  • Related MDL: MDL No. 3094, the pre-existing GLP-1 gastrointestinal injury litigation, also before Judge Marston

At least 200 NAION claims have been consolidated in the MDL, with more being added as additional patients come forward. The litigation remains in its early stages, so there have been no trials and no settlements to date.

Find out more about the latest Trulicity NAION lawsuit updates and news.

July 2026: Considering the Big Picture in Trulicity Lawsuits

The judge in the MDL decided that before any individual cases move forward, the court will first examine the scientific evidence for the link between the GLP-1s and NAION and the legal question of whether patients can sue the drug makers for not providing enough warning.

This means that specific cases won't be addressed right away. First, lawyers on both sides will gather evidence and argue about these big-picture issues. Evidence-gathering should wrap up around October 2026, and the arguments should be finished by early-to-mid 2027.

If the court decides the suits can go forward, certain cases will then be chosen to advance and help potentially settle how the rest are handled.

June 2026: Court Holds Science Day to Explore Trulicity-NAION Connection

On June 2, the court held a Science Day. This was an opportunity for both sides in the lawsuits to brief the judge on medical and scientific evidence about the connection between GLP-1 drugs and NAION.

Based on the information presented at Science Day, the court can begin to evaluate the scientific evidence behind the cases against the pharmaceutical companies and decide what expert testimony will be allowed during trials.

December 2025: Trulicity Lawsuits Consolidated in MDL

On December 15, 2025, the U.S. Judicial Panel on Multidistrict Litigation granted the request to form an MDL from GLP-1 patients experiencing vision loss. The same Pennsylvania court that was already overseeing related litigation over the gastrointestinal effects of GLP-1s centralized the NAION cases into the new MDL.

The MDL includes cases against both Eli Lilly and the Danish pharmaceutical company Novo Nordisk. In addition to Trulicity, Eli Lilly makes Mounjaro and Zepbound. Novo Nordisk manufactures Ozempic, Wegovy, Rybelsus, and Saxenda.

November 2025: Dozens of NAION Lawsuits Filed Against Trulicity Maker Eli Lilly

By late 2025, Eli Lilly faced dozens of lawsuits in both state and federal courts from people who had used GLP-1 medications like Trulicity and experienced vision loss, according to Indiana’s 13 WTHR News.

The patients in these cases shared how they decided to take legal action when they found themselves with partial vision loss while taking various GLP-1 medications.

If you believe Trulicity may have caused your vision loss, now is the time to contact Sokolove Law. Early evidence-gathering can make a meaningful difference in how your case unfolds.

Why File a Trulicity Vision Lawsuit?

A vision loss diagnosis can transform the way you travel, work, and move through your daily life. If a medication you trusted to manage your health may have caused lasting harm, you deserve answers and accountability.

Filing a Trulicity lawsuit may help you:

  • Hold Eli Lilly accountable for an alleged failure to warn about NAION
  • Pursue compensation for medical costs, lost income, and the support you may need going forward
  • Recover financial assistance tied to pain, suffering, and the lasting impact on your quality of life
  • Push for greater honesty from pharmaceutical companies about the risks their products carry

Sokolove Law has decades of experience in fighting negligent companies on behalf of patients. Let a leading Trulicity law firm put our knowledge and resources to work for you.

Find a Trulicity Lawyer Near You

Eli Lilly is one of the largest pharmaceutical companies in the world, with no shortage of attorneys working to protect their interests. Taking on a company like that requires a legal team with real experience and real resources.

Here's what you get when you choose Sokolove Law:

  • 45+ Years of Experience: Since 1979, we've represented people harmed by dangerous drugs, defective products, and corporate wrongdoing of all kinds.
  • Over $1.6 Billion Recovered: Our track record speaks for itself when it comes to securing results for clients hurt by pharmaceutical products.
  • A Truly National Practice: We represent clients in all 50 states, so wherever you live in the U.S., we can help.
  • No Upfront Cost to You: We take Trulicity cases on a contingency-fee basis, meaning you pay nothing unless we win.

You don't have to face a pharmaceutical giant on your own — and you shouldn't have to. The Trulicity lawyers at Sokolove Law has the experience and resources to fight for the compensation and justice you deserve.

Call (800) 995-1212 now or fill out our contact form to get a free, no-obligation case review.

Trulicity Lawsuit FAQs

Can Trulicity cause vision problems?

Yes, potentially. Trulicity contains dulaglutide, a GLP-1 receptor agonist. A growing body of research has examined whether GLP-1 drugs, including Trulicity, are associated with an increased risk of NAION, a sudden and typically permanent form of vision loss caused by interrupted blood flow to the optic nerve.

Pending lawsuits allege that Eli Lilly knew or should have known about this risk and failed to give patients adequate warning before they started treatment. If you developed NAION after taking Trulicity, contact Sokolove Law to explore your legal options.

Who is eligible to file a Trulicity lawsuit?

You may be eligible to file a Trulicity lawsuit if you took this medication and were later diagnosed with NAION or a similar optic nerve injury, especially if you had no history of eye problems before you started the medication.

A confirmed diagnosis from an eye care provider is generally needed to move forward with a claim. The team at Sokolove Law can review your case to find out where you stand.

Is there a class action lawsuit against Trulicity?

Rather than a class action, individual Trulicity NAION claims have been consolidated into federal multidistrict litigation along with claims against other GLP-1 medications like Ozempic, Wegovy, Mounjaro, Zepbound, Rybelsus, and Saxenda.

An MDL allows similar cases to share certain pretrial proceedings while still letting each person pursue their own individual outcome and compensation. The NAION litigation is MDL No. 3163, based in the Eastern District of Pennsylvania.

Has Eli Lilly settled any Trulicity vision loss claims?

Not at this time. As of September 2026, the NAION litigation involving Trulicity remains in its early pretrial stages.

No trials have taken place, and no global settlement has been reached. The discovery process (when the two sides share evidence, facts, and the names of witnesses) is still ongoing, and the court is reviewing the science behind Trulicity lawsuits.

Is Trulicity a high-risk medication?

GLP-1 medications like Trulicity are considered safe for most people with obesity and related conditions, according to Stanford Medicine.

However, Trulicity does carry a boxed warning from the FDA because of evidence connecting the drug with a higher chance of developing thyroid tumors and the possibility of allergic reactions.

Trulicity may also increase your risk for developing NAION, which is sudden vision loss caused by optic nerve damage. The vision loss is usually permanent.

What are the side effects of Trulicity?

Some people have experienced a range of health problems after taking Trulicity and other GLP-1 medications.

Health problems that have been linked to Trulicity include:

  • Sudden vision loss caused by NAION
  • Gastroparesis, or delayed stomach emptying
  • Acute pancreatitis
  • Gallbladder issues, including gallstones
  • Thyroid C-cell tumors, the subject of a boxed warning on Trulicity's FDA-approved label
  • Severe dehydration and related kidney complications
  • Intestinal blockage or obstruction in rare cases

If you've experienced vision loss after taking Trulicity, our team can help you understand your legal options.

How much does a leading Trulicity lawyer cost?

There are no upfront costs or hourly fees to work with our leading Trulicity lawyers. Sokolove Law handles Trulicity cases on a contingency-fee basis, meaning we only collect a fee if we recover compensation for you.

Call (800) 995-1212 now to learn more about your legal options. We’re prepared to put our experience to work for you.

Is NAION treatable?

There is currently no FDA-approved treatment that can reverse the vision loss caused by NAION. A small number of patients may see some improvement over time, but for most, the damage is permanent.

That permanence is part of why many families choose to pursue compensation from a Trulicity lawsuit. The impact on daily life and long-term finances can be significant.

How is Trulicity different from Ozempic, Wegovy, and Mounjaro?

All four belong to the broader family of GLP-1-based medications, but they're not the same drug. Trulicity contains dulaglutide and is approved for type 2 diabetes management and cardiovascular risk reduction.

However, it does not carry an FDA approval for weight loss, unlike Wegovy, which contains semaglutide and is approved specifically for chronic weight management. Ozempic also contains semaglutide but is approved for diabetes, not weight loss. Mounjaro contains tirzepatide and is likewise approved for type 2 diabetes.

Despite these differences in FDA approval and chemical makeup, all of these drugs belong to the same class and may be linked to NAION.

Managing Attorney Ricky A LeBlanc
Author: Ricky A. LeBlanc

Managing Attorney, Sokolove Law

Read Bio

Ricky A. LeBlanc is the Managing Attorney at Sokolove Law. As Managing Attorney, Ricky is responsible for all communications with prospective clients and, along with his team of paralegals and case managers, review all potential cases.

  1. 13 WTHR. “Indiana woman reports vision loss after taking GLP-1 drug; scientific research suggests drugs potentially increase risk for 'eye stroke.'” Retrieved from: https://www.wthr.com/article/news/investigations/13-investigates/indiana-woman-reports-vision-loss-after-taking-glp-1-drug-scientific-research-risk-for-eye-stroke/531-440b5141-30a7-46a4-8a2a-5c6f31ad0fae.
  2. American Academy of Ophthalmology. “Glucagon-Like Peptide-1 Receptor Agonists and the Risk of Non-Arteritic Anterior Ischemic Optic Neuropathy: A Consensus Statement by NANOS and the American Academy of Ophthalmology.” Retrieved from: https://www.aao.org/education/clinical-statement/glucagon-like-peptide-1-receptor-agonists-risk-of-.
  3. American Journal of Managed Care. "FDA Approves Dulaglutide for Adults With T2D, Regardless of CVD." Retrieved from: https://www.ajmc.com/view/fda-approves-dulaglutide-for-adults-with-t2d-regardless-of-cvd.
  4. Dr Sue (Susan Pedersen, MD). "Update: Can GLP-1 Medications Cause Loss of Vision (NAION)?" Retrieved from: https://drsue.ca/2026/01/update-can-glp1-medications-cause-loss-of-vision-naion/.
  5. Drugs.com. "Dulaglutide: Uses, Dosage, Side Effects, Warnings." Retrieved from: https://www.drugs.com/mtm/dulaglutide.html.
  6. Drugs.com. "Trulicity (dulaglutide) FDA Approval History." Retrieved from: https://www.drugs.com/history/trulicity.html.
  7. Eli Lilly. “Managing side effects.” Retrieved from: https://trulicity.lilly.com/how-to-use/side-effects.
  8. FDA Adverse Event Monitoring System (AEMS) Public Dashboard for Drugs and Biologics. "Trulicity (P)." Retrieved from: https://fis.fda.gov/sense/app/95239e26-e0be-42d9-a960-9a5f7f1c25ee/sheet/8eef7d83-7945-4091-b349-e5c41ed49f99/state/analysis.
  9. JAMA Network Open. “Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes.” Retrieved from: https://jamanetwork.com/journals/jamanetworkopen/fullarticle/2837377.
  10. JAMA Ophthalmology. “Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide.” Retrieved from: https://jamanetwork.com/journals/jamaophthalmology/fullarticle/2820255.
  11. New Zealand Medicines and Medical Devices Safety Authority (Medsafe). "Glucagon-like Peptide-1 Receptor Agonists (dulaglutide, liraglutide, semaglutide, tirzepatide) and Acute Persistent Visual Loss." Retrieved from: https://www.medsafe.govt.nz/safety/Alerts/Glucagon-like-peptide-1-receptor-agonists-and-acute-persistent-visual-loss.asp.
  12. North American Neuro-Ophthalmology Society. “Non-arteritic anterior ischemic optic neuropathy.” Retrieved from: https://www.nanosweb.org/NAION/.
  13. PR Newswire / Eli Lilly and Company. "FDA Approves Trulicity™ (dulaglutide), Lilly's Once-Weekly Therapy for Adults with Type 2 Diabetes." Retrieved from: https://www.prnewswire.com/news-releases/fda-approves-trulicity-dulaglutide-lillys-once-weekly-therapy-for-adults-with-type-2-diabetes-275661051.html.
  14. Stanford Medicine. “GLP-1s 101: What the science says about weight loss, side effects, safety.” Retrieved from: https://med.stanford.edu/news/insights/2026/06/glp1s-101-weight-loss-wegovy-ozempic-zepbound-side-effects-safe-use.html.
  15. United States District Court, Eastern District of Pennsylvania, via GovInfo. "In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation, MDL No. 3094, Memorandum Opinion." Retrieved from: https://www.govinfo.gov/content/pkg/USCOURTS-paed-2_24-md-03094/pdf/USCOURTS-paed-2_24-md-03094-2.pdf.
  16. United States District Court, Eastern District of Pennsylvania. "MDL 3163 In Re: Glucagon-like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy (NAION) Products Liability Litigation." Retrieved from: https://www.paed.uscourts.gov/mdl/mdl-3163-re-glucagon-peptide-1-receptor-agonists-glp-1-ras-non-arteritic-anterior-ischemic-optic.
  17. United States Judicial Panel on Multidistrict Litigation. "Transfer Order, MDL No. 3163, In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Non-Arteritic Anterior Ischemic Optic Neuropathy Products Liability Litigation." Retrieved from: https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3163-Transfer_Order-12-25.pdf.
  18. United States Judicial Panel on Multidistrict Litigation. "Transfer Order, MDL No. 3094, In Re: Glucagon-Like Peptide-1 Receptor Agonists (GLP-1 RAs) Products Liability Litigation." Retrieved from: https://www.jpml.uscourts.gov/sites/jpml/files/MDL-3094-Transfer_Order-1-24.pdf.